To Request an Appointment   903-592-6152

Research & Clinical Trials

Research & Clinical Trials

HOPE Center for Cancer Research - Cancer Trials

Clinical trials are an important step in research to discover new treatments that improve the health and well-being of our community.  The HOPE Center for Cancer Research is actively involved in clinical research studies and you may be eligible to participate in this important step in the pathway that leads to new treatments for cancer. Scroll down for a list of available clinical research opportunities at the HOPE Center for Cancer Research.  You may also ask your physician if participation in a clinical trial is an option for you or your loved one. 

Mission

Our mission at the HOPE Center for Clinical Research is to provide cutting edge, high-quality, clinical research opportunities to our patients so tomorrow’s medicine can reach our patients as soon as possible.

History

As the premier academic medical center in East Texas, UT Health Science Center at Tyler participates in both basic and clinical research across many disciplines, including pulmonary medicine, cardiology and cancer.   Through the years, this groundbreaking medical research and clinical trials at UTHSCT have contributed to the development of new drugs, new devices and new treatment regimens for the care of patients with a variety of conditions. 

The UT Health Science Center at Tyler and the HOPE Center for Cancer Research participates in clinical research in several tumor types, including lung, breast, colon, kidney, prostate, lymphoma and genetically targeted studies.  By participation is these studies, cancer patients in East Texas are not only provided the opportunity to take part in groundbreaking cutting-edge treatments, but also to help others and future cancer patients by the knowledge gained from their involvement in clinical research. 

Goals

Our well-established, broad based, multi-disciplinary clinical research program involves the use of new drugs and therapies and is led by our physician-scientists. Through participation in our clinical research studies and trials, research participants help us improve the quality of healthcare now and for generations to come. Fighting cancer, improving outcomes for our patients and developing the drugs of tomorrow are our primary goals. 

Who We Are

The HOPE Center for Cancer Research is a team of highly experienced clinical research professionals who support cancer clinical research and are devoted to the needs and protection of all those participating in or conducting clinical research. While maintaining high ethical standards and compliance with all regulatory policies, our team provides high-quality, efficient infrastructure, administrative and clinical support for all aspects of cancer clinical research and compassionate care to our clinical research participants and their families. 

Clinical Trials

Click the links below to see a current list of cancer clinical research opportunities. Please note that these opportunities may change at any time. For questions or additional information, you can contact the listed contact for each trial, your oncologist or Grace A Loredo, PhD, CCRP, Director of the HOPE Center for Cancer Research at 903-595-7093 or by email at grace.loredo@uthct.edu.

Protocol Title: A Phase 1b, Multicenter, Two-Part, Open-Label Study of Trastuzumab Deruxtecan, an Anti-Human Epidermal Growth Factor Receptor-2 (HER2)-ADC, in Combination with Pembrolizumab, an Anti-PD-1 Antibody, in Subjects with Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer (NSCLC)

Contact: Cristyn Cooper (903) 592-6152 ext 284

NCT04042701

More Information – https://clinicaltrials.gov/ct2/show/NCT04042701?term=ds8201-a-u106&draw=2&rank=1

 

Protocol Title: Phase 2, Open-Label Study to Evaluate the Safety and Antitumor Activity of CX-2009 in Advanced, HR-Positive/HER2-Negative Breast Cancer and of CX-2009 as Monotherapy and in Combination with CX-072 in Advanced Triple-Negative Breast Cancer

Contact: Cristyn Cooper (903) 592-6152 ext 284

NCT04596150

More Information – https://clinicaltrials.gov/ct2/show/NCT04596150?term=ctmx-2009-002&draw=...

 

Protocol Title: A Phase I-II multicenter, open label trial of H3B-6545, a covalent antagonist of estrogen receptor alpha, in women with locally advanced or metastatic estrogen receptor-positive, HER2 negative breast cancer

Contact: Cristyn Cooper (903) 592-6152 ext 284

NCT03250676

More Information – https://clinicaltrials.gov/ct2/show/NCT03250676?term=h3b-6545-a001-101&draw=2&rank=1

 

Protocol Title A Phase 2, Multi-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of IPI-549 Administered in Combination with Front-line Treatment Regimens in Patients with Locally Advanced and/or Metastatic Triple-Negative Breast Cancer or Renal Cell Carcinoma

Contact: Cristyn Cooper (903) 592-6152 ext 284

NCT03961698

More Information – https://clinicaltrials.gov/ct2/show/NCT03961698?term=ipi-549-03&draw=2&rank=1

Protocol Title: An Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without Chemotherapy, Versus Chemotherapy Alone in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer                       

Contact: Trikena Hampton (903) 595-7045

NCT04223856

More Information – https://clinicaltrials.gov/ct2/show/NCT04223856?term=sgn22e-003&draw=2&rank=1

 

There are no colorectal cancer clinical trials available at this time. 

Protocol Title: Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors – Esophageal Cancer Cohort

Contact: Cristyn Cooper (903) 592-6152 ext 284

NCT04032704

More Information – https://clinicaltrials.gov/ct2/show/NCT04032704?term=sgnlva-005&draw=2&rank=1

Protocol Title: Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors – Gastric/GEJ Cancer Cohort

Contact: Cristyn Cooper (903) 592-6152 ext 284

NCT04032704

More Information – https://clinicaltrials.gov/ct2/show/NCT04032704?term=sgnlva-005&draw=2&rank=1

Protocol Title: Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors – Head & Neck Cancer Cohort

Contact: Cristyn Cooper (903) 592-6152 ext 284

NCT04032704

More Information – https://clinicaltrials.gov/ct2/show/NCT04032704?term=sgnlva-005&draw=2&rank=1

 

Protocol Title: The BURAN Study of Buparlisib (AN2025) In Combination With Paclitaxel Compared to Paclitaxel Alone, in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma  

Contact: Cristyn Cooper (903) 592-6152 ext 284

NCT04338399

More Information – https://clinicaltrials.gov/ct2/show/NCT04338399?term=an2025h0301&draw=2&rank=1

There are no kidney cancer clinical trials available at this time.

Protocol Title: A Phase 2 Randomized Double-blind Study of Relatlimab plus Nivolumab in Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy as First Line Treatment for Participants with Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Contact: Trikena Hampton (903) 595-7045

NCT04623775

More Information – https://clinicaltrials.gov/ct2/show/NCT04623775?term=ca224-104&draw=2&rank=1

 

Protocol Title: A Phase III, Double-Blinded, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment With Atezolizumab or Placebo in Combination With Platinum-Based Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

Contact: Trikena Hampton (903) 595-7045

NCT03456063

More Information – https://clinicaltrials.gov/ct2/show/NCT03456063?term=go40241&draw=2&rank=1

 

Protocol Title: A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer     

Contact: Cristyn Cooper (903) 592-6152 ext 284

NCT04262856

More Information – https://clinicaltrials.gov/ct2/show/NCT04262856?term=ab154csp0002&draw=2&rank=1

 

Protocol Title: Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors – Non-Small Cell Lung Cancer Cohort

Contact: Cristyn Cooper (903) 592-6152 ext 284

NCT04032704

More Information – https://clinicaltrials.gov/ct2/show/NCT04032704?term=sgnlva-005&draw=2&rank=1

 

Protocol Title: A Phase 1b, Multicenter, Two-Part, Open-Label Study of Trastuzumab Deruxtecan, an Anti-Human Epidermal Growth Factor Receptor-2 (HER2)-ADC, in Combination with Pembrolizumab, an Anti-PD-1 Antibody, in Subjects with Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer (NSCLC)

Contact: Cristyn Cooper (903) 592-6152 ext 284

NCT04042701

More Information – https://clinicaltrials.gov/ct2/show/NCT04042701?term=ds8201-a-u106&draw=2&rank=1

 

Protocol Title: A Phase 1b/3 double-blind, randomized, active-controlled, 3-stage, biomarker adaptive study of tazemetostat or placebo in combination with lenalidomide plus rituximab in subjects with relapsed/refractory follicular lymphoma

Contact: Trikena Hampton (903) 595-7045

NCT04224493

More Information – https://clinicaltrials.gov/ct2/show/NCT04224493?term=ezh-302&draw=2&rank=1

 

Protocol Title: A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)

Contact: Cristyn Cooper (903) 592-6152 ext 284

NCT04442022

More Information – https://clinicaltrials.gov/ct2/show/NCT04442022?term=xport-dlbcl-030&draw=2&rank=1

Protocol Title: Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors – Melanoma Cohort           

Contact: Cristyn Cooper (903) 592-6152 ext 284

NCT04042701

More Information – https://clinicaltrials.gov/ct2/show/NCT04042701?term=ds8201-a-u106&draw=2&rank=1

Protocol Title: A Phase 3, Randomized, Double-Blind Study of Nivolumab or Placebo in Combination With Docetaxel, in Men With Metastatic Castration-resistant Prostate Cancer             

Contact: Cristyn Cooper (903) 592-6152 ext 284

NCT04100018

More Information – https://clinicaltrials.gov/ct2/show/NCT04100018?term=ca209-7dx&draw=2&rank=1

 

Protocol Title: Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors – Castrate Resistant, Metastatic Prostate Cancer Cohort           

Contact: Cristyn Cooper (903) 592-6152 ext 284

NCT04042701

More Information – https://clinicaltrials.gov/ct2/show/NCT04042701?term=ds8201-a-u106&draw=2&rank=1

Clinical research opportunities are also available for drugs that target the presence of a specific genetic mutation in the tumor rather than a specific cancer type.  Drugs that are designed to be effective against a specific mutation in a patient’s tumor are known as targeted therapies, precision medicine or personalized medicine. If you have not had analysis of your cancer, ask your doctor if you are eligible for mutation testing

Protocol Title: Tumor-Agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial

Targeted Mutations: ROS1; NTRK1/2/3; ALK; TMB high; AKT1/2/3; HER2; MDM2; PIK3CA; BRAF; RET

Contact: Grace Loredo (903) 595-7093

NCT04589845

More Information – https://clinicaltrials.gov/ct2/show/NCT04589845?term=tapistry&draw=2&rank=1

At UT Health East Texas HOPE Cancer Center we understand how a cancer diagnosis — and cancer treatment — can impact your life. That’s because we’ve been helping East Texans fight cancer for more than 30 years… with the same leading-edge treatments and care offered at large cancer centers in major metropolitan areas.

UT Health East Texas HOPE Cancer Center is owned and operated by UT Health North Campus Tyler. Our Tyler, Henderson and Jacksonville locations operate as departments of UT Health North Campus Tyler.

 

©2021 UT Health East Texas HOPE Cancer Center. All Rights Reserved.

UT Health East Texas HOPE Cancer Center

721-A Clinic Drive Tyler, TX 75701 903-592-6152

Privacy Policy